Today: 11 June 2026
Browse Category

ASX:BAN 3 February 2026

Stock Market Today

  • Propanc Biopharma Shares Surge on $5 Million Buyback Plan Despite Cash Woes
    June 11, 2026, 11:03 AM EDT. Propanc Biopharma shares soared on Nasdaq Thursday after announcing a $5 million stock buyback plan, signaling management confidence despite the company's cash balance of just $443,702 as of March 31. The buyback authorization exceeds the company's roughly 2.28 million shares outstanding post-reverse split, prompting investor optimism. CEO James Nathanielsz highlighted the upcoming Phase 1b trial of PRP in advanced cancer patients and its FDA orphan drug status in pancreatic cancer as key drivers. However, Propanc reported a net loss of $14.29 million over nine months and flagged 'substantial doubt' about its ability as a going concern without additional funding. The company cautioned the buyback plan does not guarantee share purchases, leaving execution uncertain amid tight finances.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Go toTop